Photo from wikipedia
Osimertinib (AZD9291 or TAGRISSO™) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) developed to overcome T790M-induced resistance, which accounts for approximately 60% of resistant cases after 1… Click to show full abstract
Osimertinib (AZD9291 or TAGRISSO™) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) developed to overcome T790M-induced resistance, which accounts for approximately 60% of resistant cases after 1 st generation EGFR-TKI treatment. Beyond T790M mutation, osimertinib also selectively and irreversibly inhibits EGFR harboring the common “sensitive” mutations such as 19del and L858R.
Keywords:
treatment discriminate;
treatment;
osimertinib treatment;
young patients;
discriminate young
Journal Title: Journal of thoracic disease
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of thoracic disease
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!